Dr. John Cush RheumNow
2 years 5 months ago
JAMA review of ILD; that affects 650,000 in USA, leading to 25,000-30,000 deaths/YR. Types reviewed. Key Symptoms: dyspnea and cough, w/ chest CT being diagnostic tool. Antifibrotic & immunomodulatory may slow disease progression. https://t.co/xegChTUysM https://t.co/6GMJCqjoBx
Machine learning (ML) models were applied to 3 cohorts of lupus nephritis (LN) patients and established algorithms to predict co-infection in LN. This study analyzed 111 non-infected LN patients, 72 infected LN patients, and 206 healthy controls (HCs), looking at patient demographics, infection outcomes, medication, and laboratory indexes (including cell counts and lymphocyte subsets).
Dr. John Cush RheumNow
2 years 5 months ago
Is Colchicine Rx a problem? Retrospective study of UK Clinical Practice registry, 13945 gout initiated allopurinol with colchicine (64yrs; 78% male). 26% on 1+ meds interacting w/ colchicine. Diarrhea & MI more freq w/ comorbidities & more severe CKD https://t.co/Y2boo9gcg2 https://t.co/aqUGMooXto
Dr. John Cush RheumNow
2 years 5 months ago
Self Acupressure in Knee Osteoarthritis
A clinical trial has shown that self-administered acupressure (SAA) is effective in relieving knee osteoarthritis (KOA) patients.
https://t.co/jwP25u7J0b https://t.co/PH3aOoJaDu
Dr. John Cush RheumNow
2 years 5 months ago
ICYMI: How do you manage enthesitis?
https://t.co/8cuKz1Ddpb https://t.co/3KMKQCVDSN
An observational cohort study suggests that proteinuria levels in lupus nephritis (LN) patients did not predict their histologic class.
A multicentre observational study of patients with biopsy-proven LN; either proliferative (PLN) or membranous (MLN) lupus nephritis were compared regarding clinical and laboratory presentation and long-term outcomes. The primary outcome was progression to chronic kidney disease (CKD).
Dr. John Cush RheumNow
2 years 5 months ago
50 active RA pts RCT Rx w. either low dose IL-2(n=26), IL-2+TCZ (9) or control (15). All improved clinically by DAS28-ESR, but IL-2 Rx pts had signif proliferation of Tregs, w. decr inTh1, Th2, & Th17 cells. TREG #s correlated w/ ESR drop (r=0.54) https://t.co/1tF63FuXzx https://t.co/M5TWsa6zI4
Dr. John Cush RheumNow
2 years 5 months ago
Single center retrospective 173 pts w/ CTD-ILD - 34% Sjogren’s, 30 RA, 25 systemic sclerosis, 6 UCTD, 3% idiopathic inflam myositis, 1,2% MCTD, 0.6% SLE. NSIP most common (60%) inSS & SSc; UIP more common in RA. 6 died, mostly infection https://t.co/IL2tnVDtoQ https://t.co/Ada49Qv5XL
Dr. John Cush RheumNow
2 years 5 months ago
'Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases’ - a 6 center consortium will study if JAKi (filgotinib) is effective and safe in 3 rare disorders -- Behcets, inflammatory myositis & IgG4 related disease. https://t.co/2gKCKEl7Ml https://t.co/yTrvFzFUgf
Continuing with the theme of clinical pearls, the PsA and SpA speakers also provided a wealth of information. Here are my five key takeaways and clinical pearls.
Dr. John Cush RheumNow
2 years 5 months ago
SGLT2 Inhibitors Lowers Gout Risks in Type 2 Diabetes
A population-based cohort has demonstrated tha SGLT2i use in gout patients is superior to sulfonylurea therapy in lowering the risk of incident gout and recurrent flares among patients withT2D.
https://t.co/QZ7bt39zEW https://t.co/Wlo9SF0hPF
Dr. John Cush RheumNow
2 years 5 months ago
STEP 9 - a, multinational phase 3 RCT studied semaglutide vs PBO in 407 Knee OA (Gr2-3) pts w/ pain >4/10 & BMI >30 (mean 40.3; mean WOMAC 71). At wk 68 SEM > PBO lowering WOMAN pain (-42 v -27; p<.001). Wt loss: 13.7% v 3.2%, respectively. https://t.co/101qML0wQM https://t.co/tG3hk5Wy5E
Dr. John Cush RheumNow
2 years 5 months ago
Articular Findings Sarcoidosis:
- Acute arthritis: Lg Jt Oligoarthritis; Loffgrens syndrome (hilar LN, arthritis, E. nodosum)
- Acute > Chronic arthritis
- Chronic arthritis: tenosynovitis, oligo- &polyarthritis, dactylitis, erosions or Jaccouds arthritis
https://t.co/zDLJqsjnbj https://t.co/lo6UIlhka3
